While these agents have transformed outcomes in HER2-positive breast and gastric cancers, resistance frequently develops through HER2 mutations, receptor shedding, epitope masking, signaling pathway reactivation, or immune evasion mechanisms (46, 49). Here, ERBB2 is linked to gastric cancer.